期刊文献+

大剂量促红细胞生成素治疗肾性贫血的疗效观察 被引量:7

Observation of Therapeutic Effects of Large Dose of Erythropoietin in the Treatment of Patients with Renal Anemia
下载PDF
导出
摘要 目的:观察大剂量促红细胞生成素治疗肾性贫血的疗效和安全性。方法:将60例肾性贫血患者随机分为治疗组和对照组。治疗组给予促红细胞生成素9000IU皮下注射,1次/wk;对照组给予促红细胞生成素3000IU皮下注射,3次/wk,均连用6wk。结果:治疗组和对照组的有效率分别为93.3%、90.0%(P>0.05),但前者较后者每周注射次数减少,费用低,且不良反应无明显增加。结论:大剂量促红细胞生成素治疗肾性贫血疗效确切、安全、可靠。 OBJECTIVE:To observe the curative effects and safety of large dose of erythropoietin in the treatment of renal anemia.METHODS:60patients with renal anemia were randomized into treatment group and control group.The treatment group was given erythropoietin9000IU by hypodermic injection once a week;the control group was treated with erythropoietin3000IU by hypodermic injection3times a week.The course of treatment for both group were6successive weeks.RESULTS:The effective rates of the treatment group and the control group were93.3%and90.0%(P>0.05)respectively,but the weekly injection times of the treatment group were reduced and the cost was lower as against the control group and there was no significant increase of adverse reactions in the treatment group.CONCLUSION:It is effective,safe and reliable to use large dose of erythropoietin in the treatment of renal anemia.
作者 张萍 梁劲松
出处 《中国药房》 CAS CSCD 北大核心 2005年第13期1009-1010,共2页 China Pharmacy
关键词 慢性肾功能衰竭 贫血 促红细胞生成素 疗效 Chronic renal failure Anemia Erythropoietin Curative effects
  • 相关文献

参考文献5

二级参考文献18

  • 1季曙明,黎磊石.应用重组促红细胞生成素治疗长期血透患者贫血[J].中华内科杂志,1993,32(2):100-102. 被引量:6
  • 2郑法雷,毕增祺.小剂量红细胞生成素对透析前慢性肾衰患者贫血的作用[J].中华内科杂志,1993,32(7):440-443. 被引量:8
  • 3[1]Winearls CG. Recombinant human erythropoietin: 10 years of clinical experience. Nephrol Dial Transplant, 1998, 13(Suppl 2):3-8
  • 4[2]Wagstaff AJ. Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients. Drugs Aging,1995, 7(2):131-56
  • 5[3]House AA, Pham B,Pag DE. Transfusion and recombinant human erythropoietin requirements differ between dialysis modalities. Nephrol Dial Transplant, 1996, 13(7):1763-9
  • 6[4]Jones MA,Kingswood JC,Dallyn PE, et al. Haemodynamic changes measured by transthoracic bioimpedance during treatment with recombinant human erythropoietin. Clin Exp Hypertens ,1996, 18(1):51-64
  • 7[5]Sundal E,Kaeser U.Correction of anaemia of chronic renal failure with recombinant human erythropoietin:safety and efficacy of one year's treatment in a European Multicentre Study of 150 haemodiaysis-dependent patients.Nephrol Dial Transplant,1989,4:979-987
  • 8[6]Parker KP,Mitch WE, Stivelman JC, et al. Safety and efficacy of low-dose subcutaneous erythropoietin in hemodiaysis patients. J Am Soc Nephrol,1997,8:288-293
  • 9[7]Eschbanh JW.The anemia of chronic renal failure:Pathophysiology and effects of recombinant erythropoietin. Kidney Int,1989,35:134-148
  • 10[8]Winearls CG,Oliver DO,Pippard MJ, et al. Effect of human erythropoietin derived from recombinant DNA on the anaemian of patients maintained by chronec haemodialysis. Lanct,1986,2:1175-1178

共引文献43

同被引文献45

引证文献7

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部